Cited by 550Influenza Virus Research StudiesRespiratory viral infections researchBacterial Infections and Vaccines

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza: Randomized Controlled Trials for Prevention and Treatment

Hayden, Frederick G., Treanor, John J., Fritz, R. Scott, Lobo, Monica, Betts, Robert F., Miller, Madeline, Kinnersley, Nelson, Mills, Roger G., Ward, Penelope, Straus, Stephen E.·1999·JAMA

DOI 10.1001/jama.282.13.1240

Open this paper in CoChat — free account

Abstract

CONTEXT: Influenza virus neuraminidase is thought to be essential for virus replication in humans; however, to date, available neuraminidase inhibitors are limited to zanamivir, which is topically administered. OBJECTIVE: To determine the safety, tolerability, and antiviral activity of oral neuraminidase inhibitor oseltamivir (GS4104/Ro64-0796) for prevention and the early treatment of influenza in experimentally infected humans. DESIGN: Two randomized, double-blind, placebo-controlled trials conducted between June and July 1997. SETTING: Individual hotel rooms; 2 large US university medical schools. PARTICIPANTS: A total of 117 healthy adult volunteers (aged 18-40 years; median age, 21 years) who were susceptible (hemagglutination-inhibition antibody titer < or =1:8). INTERVENTIONS: All subjects were inoculated intranasally with influenza A/Texas/36/91 (H1N1) virus. For the prophylaxis study, oral oseltamivir (100 mg once daily [n = 12], 100 mg twice daily [n = 12], or matching placebo [n = 13], starting 26 hours before virus inoculation) was administered. For the treatment study, the same drug was given (20 mg, 100 mg, or 200 mg twice daily, 200 mg once daily, or matching placebo [n = 16], in each group starting 28 hours after inoculation). All regimens were continued for 5 days. MAIN OUTCOME MEASURES: Comparing placebo groups with pooled treatment groups, for prophylaxis, outcomes included frequency of infection and viral shedding; for treatment, viral shedding in titers. RESULTS: In the prophylaxis study, 8 (67%) of 12 placebo and 8 (38%) of 21 oseltamivir recipients became infected (P = .16; efficacy, 61%); 6 (50%) placebo compared with 0 oseltamivir recipients shed virus (P<.001; efficacy, 100%), and 33% of placebo but no oseltamivir recipient had infection-related respiratory illness (P<.01). Among infected subjects in the treatment study (n = 69), the viral titer area under the curve of the combined oseltamivir groups (n = 56) was lower (median [interquartile range [IQR]], 80 [23-151] vs 273 [79-306] log10 tissue culture-infective doses50 per milliliter x hour; P = .02) than the placebo group (n = 13), and the median (IQR) duration of viral shedding with therapy was reduced from 107 (83-131) to 58 (35-59) hours (P = .003). Oseltamivir treatment also reduced symptom scores (median [IQR] score-hours, 225 [97-349] vs 400 [189-645]; P = .05), and nasal proinflammatory cytokine levels. Transient mild to moderate nausea after dosing was observed in 15 (17%) of 88 oseltamivir and 2 (7%) of 29 placebo recipients (95% confidence interval for difference, -11% to 68%), which was largely prevented by ingestion with food. CONCLUSIONS: In these trials, prophylaxis and early treatment with oral oseltamivir were both associated with significant antiviral and clinical effects in experimental human influenza.

Integrity signals

Registry

Crossref · 10.1001/jama.282.13.1240

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Rational design of potent sialidase-based inhibitors of influenza virus replication
von Itzstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., et al. (1993) · Nature · doi:10.1038/363418a0 · Cited by 1,862
Influenza Neuraminidase Inhibitors Possessing a Novel Hydrophobic Interaction in the Enzyme Active Site: Design, Synthesis, and Structural Analysis of Carbocyclic Sialic Acid Analogues with Potent Anti-Influenza Activity
Kim, C. U., Lew, W., Williams, M. A., Liu, H., Zhang, L., Swaminathan, S., Bischofberger, N., Chen, M. S., Mendel, D. B., Tai, C. Y., et al. (1997) · Journal of the American Chemical Society · doi:10.1021/ja963036t · Cited by 1,100
Structure of the catalytic and antigenic sites in influenza virus neuraminidase
Colman, P. M., Varghese, J. N., & Laver, W. G. (1983) · Nature · doi:10.1038/303041a0 · Cited by 806
Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections
Hayden, F. G., Osterhaus, A. D. M. E., Treanor, J. J., Fleming, D. M., Aoki, F. Y., Nicholson, K. G., Bohnen, A. M., Hirst, H. M., Keene, O., & Wightman, K. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371302 · Cited by 762
Self-citation
Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense.
Hayden, F. G., Fritz, R., Lobo, M. C., Alvord, W. G., Strober, W., & Straus, S. E. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1355 · Cited by 680
Self-citation
The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor
Varghese, J. N., McKimm‐Breschkin, J. L., Caldwell, J. B., Kortt, A. A., & Colman, P. M. (1992) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.340140302 · Cited by 402
Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding
Liu, C., Eichelberger, M. C., Compans, R. W., & Air, G. M. (1995) · Journal of Virology · doi:10.1128/jvi.69.2.1099-1106.1995 · Cited by 366
Influenza virus neuraminidase: Structure, antibodies, and inhibitors
Colman, P. M. (1994) · Protein Science · doi:10.1002/pro.5560031007 · Cited by 334
Safety and Efficacy of the Neuraminidase Inhibitor GG167 in Experimental Human Influenza
Hayden, F. G. (1996) · JAMA · doi:10.1001/jama.1996.03530280047035 · Cited by 291
Self-citation
Oral Administration of a Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071 Protects Mice and Ferrets against Influenza Infection
Mendel, D. B., Tai, C. Y., Escarpe, P. A., Li, W., Sidwell, R. W., Huffman, J. H., Sweet, C., Jakeman, K. J., Merson, J. R., Lacy, S. A., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.640 · Cited by 253

Show all 30 references

Sorted by citations

Items 201–300 of 547

Clinical Efficacy and Safety of the Selective Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza
Kashiwagi, S., Kudoh, S., Watanabe, A., & Yoshimura, I. (2000) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi1970.74.1044 · Cited by 41
Health outcomes among patients receiving oseltamivir
Enger, C. L., Nordstrom, B. L., Thakrar, B. T., Sacks, S. T., & Rothman, K. J. (2003) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.845 · Cited by 41
Passivity-Based Inverse Optimal Impulsive Control for Influenza Treatment in the Host
Hernández-Mejía, G., Alanís, A. Y., Hernandez‐Gonzalez, M., Findeisen, R., & Hernandez-Vargas, E. A. (2019) · IEEE Transactions on Control Systems Technology · doi:10.1109/tcst.2019.2892351 · Cited by 41
Influenza Outbreak Detection and Control Measures in Nursing Homes in the United States
Zadeh, M. M., Bridges, C. B., Thompson, W., Arden, N. H., & Fukuda, K. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb02606.x · Cited by 41
Neuraminidase inhibitors for the treatment and prevention of influenza
McKimm‐Breschkin, J. L. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.2.103 · Cited by 41
Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Influenza and HIV: Lessons from the 2009 H1N1 Influenza Pandemic
Sheth, A. N., Patel, P., & Peters, P. J. (2011) · Current HIV/AIDS Reports · doi:10.1007/s11904-011-0086-4 · Cited by 40
Clinical Benefits with Oseltamivir in???Treating Influenza in Adult Populations
Singh, S., Barghoorn, J., Bagdonas, A., Adler, J., Treanor, J. J., Kinnersley, N., & Ward, P. (2003) · Clinical Drug Investigation · doi:10.2165/00044011-200323090-00002 · Cited by 40
Self-citation
Characterization of the Localized Immune Response in the Respiratory Tract of Ferrets following Infection with Influenza A and B Viruses
Carolan, L. A., Rockman, S., Borg, K., Guarnaccia, T. A., Reading, P. C., Mosse, J., Kelso, A., Barr, I., & Laurie, K. (2015) · Journal of Virology · doi:10.1128/jvi.02797-15 · Cited by 39
Detection of influenza A H1N1 and H3N2 mutations conferring resistance to oseltamivir using rolling circle amplification
Steain, M. C., Dwyer, D. E., Hurt, A. C., Kol, C., Saksena, N. K., Cunningham, A. L., & Wang, B. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.09.010 · Cited by 38
Influenza virus shedding—Excretion patterns and effects of antiviral treatment
Aoki, F. Y., & Boivin, G. (2009) · Journal of Clinical Virology · doi:10.1016/j.jcv.2009.01.010 · Cited by 39
Antiviral Agents for Influenza
Lynd, L. D., Goeree, R. A., & OʼBrien, B. J. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523110-00003 · Cited by 38
Differential evolution of peripheral cytokine levels in symptomatic and asymptomatic responses to experimental influenza virus challenge
McClain, M. T., Henao, R., Williams, J., Nicholson, B., Veldman, T., Hudson, L., Tsalik, E. L., Lambkin‐Williams, R., Gilbert, A., Mann, A., et al. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12736 · Cited by 37
In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus
Tarbet, E. B., Vollmer, A. H., Hurst, B. L., Barnard, D. L., Furuta, Y., & Smee, D. F. (2013) · Archives of Virology · doi:10.1007/s00705-013-1922-1 · Cited by 37
Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus
Baz, M., Carbonneau, J., Rhéaume, C., Cavanagh, M.-H., & Boivin, G. (2018) · Viruses · doi:10.3390/v10110610 · Cited by 37
Effectiveness of Neuraminidase Inhibitors for Preventing Staff Absenteeism during Pandemic Influenza
Lee, V. J., & Chen, M. I.-C. (2007) · Emerging infectious diseases · doi:10.3201/eid1303.060309 · Cited by 37
Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung
Wong, Z. X., Jones, J. E. C., Anderson, G. P., & Gualano, R. C. (2011) · Influenza and Other Respiratory Viruses · doi:10.1111/j.1750-2659.2011.00235.x · Cited by 36
The mechanisms of sudden-onset type adverse reactions to oseltamivir
Hama, R., & Bennett, C. L. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12629 · Cited by 36
Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact
Oh, D. Y., Lowther, S., McCaw, J. M., Sullivan, S. G., Leang, S.-K., Haining, J., Arkinstall, R., Kelso, A., McVernon, J., Barr, I., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku146 · Cited by 35
Oseltamivir–zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections
Escuret, V., Cornu, C., Boutitie, F., Enouf, V., Mosnier, A., Bouscambert‐Duchamp, M., Gaillard, S., Duval, X., Blanchon, T., Leport, C., et al. (2012) · Antiviral Research · doi:10.1016/j.antiviral.2012.08.002 · Cited by 35
Efficacy of Single Intravenous Injection of Peramivir against Influenza B Virus Infection in Ferrets and Cynomolgus Macaques
Kitano, M., Itoh, Y., Kodama, M., Ishigaki, H., Nakayama, M., Ishida, H., Baba, K., Noda, T., Sato, K., Nihashi, Y., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00412-11 · Cited by 34
Studies on Influenza Virus Transmission between Ferrets: the Public Health Risks Revisited
Fouchier, R. A. M. (2015) · mBio · doi:10.1128/mbio.02560-14 · Cited by 34
The Mechanisms for Within-Host Influenza Virus Control Affect Model-Based Assessment and Prediction of Antiviral Treatment
Cao, P., & McCaw, J. M. (2017) · Viruses · doi:10.3390/v9080197 · Cited by 33
In vitro and in vivo Protection against the Highly Pathogenic H5N1 Influenza virus by an Antisense Phosphorothioate Oligonucleotide
Duan, M., Zhou, Z., Lin, R., Yang, J., Xia, X., & Wang, S. (2008) · Antiviral Therapy · doi:10.1177/135965350801300112 · Cited by 33
Influenza in the Intensive Care Unit
Oliveira, E. C., Lee, B., & Colice, G. (2003) · Journal of Intensive Care Medicine · doi:10.1177/0885066602250368 · Cited by 34
Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice
Burger, R. A., Billingsley, J. L., Huffman, J. H., Bailey, K. W., Kim, C. U., & Sidwell, R. W. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(99)00184-8 · Cited by 33
The mechanisms of delayed onset type adverse reactions to oseltamivir
Hama, R. (2016) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2016.1189592 · Cited by 33
Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms
Dobrovolny, H. M., & Beauchemin, C. A. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180582 · Cited by 32
Investigating Different Mechanisms of Action in Combination Therapy for Influenza
Melville, K., Rodriguez, T., & Dobrovolny, H. M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01207 · Cited by 32
Umifenovir susceptibility monitoring and characterization of influenza viruses isolated during ARBITR clinical study
Leneva, I. A., Falynskova, I. N., Makhmudova, N. R., Поромов, А. А., Yatsyshina, S. B., & Vv, M. (2018) · Journal of Medical Virology · doi:10.1002/jmv.25358 · Cited by 32
Intervention strategies for an influenza pandemic taking into account secondary bacterial infections
Handel, A., Longini, I. M., & Antia, R. (2009) · Epidemics · doi:10.1016/j.epidem.2009.09.001 · Cited by 33
Clinical aspects and cytokine response in adults with seasonal influenza infection.
Bian, J., Nie, W., Zang, Y., Fang, Z., Xiu, Q., & Xu, X. (2014) · PubMed Central · Cited by 32
Oseltamivir in the management of influenza
OXFORD, J. S. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.14.2493 · Cited by 32
The role of sialidases in the pathogenesis of bacterial vaginosis and their use as a promising pharmacological target in bacterial vaginosis
Chen, L., Li, J., & Xiao, B. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1367233 · Cited by 31
T-705 (Favipiravir) suppresses tumor necrosis factor α production in response to influenza virus infection: A beneficial feature of T-705 as an anti-influenza drug
Tanaka, T., KAMIYAMA, T., Daikoku, T., Takahashi, K., NOMURA, N., Kurokawa, M., & Shiraki, K. (2017) · Acta Virologica · doi:10.4149/av_2017_01_48 · Cited by 31
Intake of 25-hydroxyvitamin D3 reduces duration and severity of upper respiratory tract infection: A randomized, double-blind, placebo-controlled, parallel group comparison study
Shimizu, Y., Ito, Y., Yui, K., Egawa, K., & Orimo, H. (2017) · The journal of nutrition health & aging · doi:10.1007/s12603-017-0952-x · Cited by 32
Risk of neuropsychiatric adverse events associated with the use of oseltamivir: a nationwide population-based case-crossover study
Kang, H., Lee, E., Kim, W. J., & Shin, J.-Y. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky445 · Cited by 31
Antiviral Agents for Non-Human Immunodeficiency Virus Infections
Keating, M. R. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.12.1266 · Cited by 31
Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults
Postma, M. J., Jansema, P., Scheijbeler, H., & van Genugten, M. L. L. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.06.007 · Cited by 32
Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005.
Peters, P. H., Moscona, A., Schulman, K. L., & Barr, C. E. (2008) · PubMed Central · Cited by 30
Therapeutics Against Influenza
Govorkova, E. A., & McCullers, J. A. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_198 · Cited by 30
Subclinical Avian Influenza A(H5N1) Virus Infection in Human, Vietnam
Le, M. Q., Horby, P., Fox, A., Nguyen, H. T., Nguyen, H. K., Hoang, P. M. V., Nguyen, K. C., de Jong, M. D., Jeeninga, R. E., van Doorn, H. R., et al. (2013) · Emerging infectious diseases · doi:10.3201/eid1910.130730 · Cited by 30
Impact of Influenza Treatment with Oseltamivir on Health, Sleep and Daily Activities of Otherwise Healthy Adults and Adolescents
Bettis, R. B., Iacuzio, D. A., Jung, T., Fuchs, R., Aultman, R., & Gyldmark, M. (2006) · Clinical Drug Investigation · doi:10.2165/00044011-200626060-00004 · Cited by 30
Performance of Directigen flu A+B enzyme immunoassay and direct fluorescent assay for detection of influenza infection during the 2004–2005 season
Rahman, M., Kieke, B. A., Vandermause, M., Mitchell, P. D., Greenlee, R. T., & Belongia, E. A. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.03.011 · Cited by 30
Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes
Orzeck, E. A., Shi, N., & Blumentals, W. A. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.10.001 · Cited by 30
Oseltamivir Pharmacokinetics and Clinical Experience in Neonates and Infants during an Outbreak of H1N1 Influenza A Virus Infection in a Neonatal Intensive Care Unit
Standing, J. F., Nika, A., Tsagris, V., Kapetanakis, I., Maltezou, H. C., Kafetzis, D. A., & Tsolia, M. N. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00290-12 · Cited by 30
Pharmacokinetic-Pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies
Rayner, C. R., Bulik, C. C., Kamal, M. A., Reynolds, D. K., Toovey, S., Hammel, J., Smith, P. F., Bhavnani, S. M., Wart, S. A. V., Ambrose, P. G., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02440-12 · Cited by 30
Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial
Deng, R., Lee, A. P., Maia, M., Lim, J. J., Burgess, T., Horn, P., Derby, M. A., Newton, E. M., Tavel, J. A., & Hanley, W. D. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0564-y · Cited by 30
New point of care test is highly specific but less sensitive for influenza virus A and B in children and adults
Rawlinson, W. D., Waliuzzaman, Z., Fennell, M., Appleman, J. R., Shimasaki, C. D., & Carter, I. W. J. (2004) · Journal of Medical Virology · doi:10.1002/jmv.20155 · Cited by 30
The course of fever following influenza virus infection in children treated with oseltamivir
Suzuki, E., & Ichihara, K. (2008) · Journal of Medical Virology · doi:10.1002/jmv.21144 · Cited by 29
Virus-based SELEX (viro-SELEX) allows development of aptamers targeting knotty proteins
Narayan, C., Kwon, J., Kim, C., Kim, S., & Jang, S. K. (2019) · The Analyst · doi:10.1039/c9an01943j · Cited by 29
Improving Outcomes of Elderly Patients with Community-Acquired Pneumonia
Gutiérrez, F., & Masiá, M. (2008) · Drugs & Aging · doi:10.2165/00002512-200825070-00005 · Cited by 29
Impact of antiviral treatment and hospital admission delay on risk of death associated with 2009 A/H1N1 pandemic influenza in Mexico
Chowell, G., Viboud, C. G., Simonsen, L., Miller, M. A., Echevarría‐Zuno, S., González-León, M., & Aburto, V. H. B. (2012) · BMC Infectious Diseases · doi:10.1186/1471-2334-12-97 · Cited by 29
Self-citation
Effectiveness of post-exposition prophylaxis with oseltamivir in nursing homes: a randomised controlled trial over four seasons
van der Sande, M. A. B., Meijer, A., Şen-Kerpiclik, F., Enserink, R., Cools, H. J. M., Overduin, P., Ferreira, J. M., Veldman-Ariesen, M. J., & For the Peppie study group (2014) · Emerging Themes in Epidemiology · doi:10.1186/1742-7622-11-13 · Cited by 31
An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection
Lambkin‐Williams, R., Gelder, C. M., Broughton, R., Mallett, C. P., Gilbert, A. S., Mann, A., He, D. Y., OXFORD, J. S., & Burt, D. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163089 · Cited by 29
Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses
Pickens, J. A., & Tripp, R. A. (2018) · Viruses · doi:10.3390/v10010048 · Cited by 30
The role of oseltamivir in the treatment and prevention of influenza in children
Whitley, R. J. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425225.3.5.755 · Cited by 29
Oseltamivir
Tullu, M. S. (2009) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.57411 · Cited by 29
A Genomic Signature of Influenza Infection Shows Potential for Presymptomatic Detection, Guiding Early Therapy, and Monitoring Clinical Responses
McClain, M. T., Nicholson, B. P., Park, L. P., Liu, T.-Y., Hero, A. O., Tsalik, E. L., Zaas, A. K., Veldman, T., Hudson, L. L., Lambkin-Williams, R., et al. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw007 · Cited by 28
Model answers or trivial pursuits? The role of mathematical models in influenza pandemic preparedness planning
McVernon, J., McCaw, C., & Mathews, J. D. (2007) · Influenza and Other Respiratory Viruses · doi:10.1111/j.1750-2659.2007.00008.x · Cited by 28
How Can Viral Dynamics Models Inform Endpoint Measures in Clinical Trials of Therapies for Acute Viral Infections?
Vegvari, C., Hadjichrysanthou, C., Cauët, E., Lawrence, E., Cori, A., de Wolf, F., & Anderson, R. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158237 · Cited by 28
Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study
Sloan, S. E., Szretter, K. J., Sundaresh, B., Narayan, K. M., Smith, P. F., Skurnik, D., Bedard, S., Trevejo, J., Oldach, D., & Shriver, Z. H. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104763 · Cited by 28
Development of an HTS Assay for the Search of Anti-influenza Agents Targeting the Interaction of Viral RNA with the NS1 Protein
Maroto, M., Fernández, Y., Ortı́n, J., Peláez, F., & Cabello, M. A. (2008) · SLAS DISCOVERY · doi:10.1177/1087057108318754 · Cited by 28
Prophylaxis and treatment of influenza: options, antiviral susceptibility, and existing recommendations
Duwe, S. C., Schmidt, B., Gärtner, B. C., Timm, J., Adams, O., Fickenscher, H., & Schmidtke, M. (2021) · PubMed Central · doi:10.3205/id000071 · Cited by 28
Influenza virus and rhinovirus-related otitis media: potential for antiviral intervention
Hayden, F. G. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00281-4 · Cited by 28
Self-citation
Development of a multiplex isothermal amplification molecular diagnosis method for on-site diagnosis of influenza
Jang, W. S., Lim, D. H., Nam, J., Mihn, D.-C., Sung, H. W., Lim, C. S., & Kim, J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238615 · Cited by 27
Interferon-Induced Expression of MxA in the Respiratory Tract of Rhesus Macaques Is Suppressed by Influenza Virus Replication
Carroll, T. D., Matzinger, S. R., Genescà, M., Fritts, L., Colón, R., McChesney, M. B., & Miller, C. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2385 · Cited by 27
A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression
Kamal, M. A., Gieschke, R., Lemenuel‐Diot, A., Beauchemin, C. A. A., Smith, P. F., & Rayner, C. R. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00069-15 · Cited by 27
Limited replication of influenza A virus in human mast cells
Marcet, C. T., Laurent, C. D. S., Moon, T. C., Singh, N. T., & Befus, A. D. (2012) · Immunologic Research · doi:10.1007/s12026-012-8377-4 · Cited by 27
Leucomycin A3, a 16-membered macrolide antibiotic, inhibits influenza A virus infection and disease progression
Sugamata, R., Sugawara, A., Nagao, T., Suzuki, K., Hirose, T., Yamamoto, K., Oshima, M., Kobayashi, K., Sunazuka, T., Akagawa, K. S., et al. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2013.132 · Cited by 27
Severe influenza treatment guideline
Choi, W. S., Baek, J. H., Seo, Y. B., Kee, S. Y., Jeong, H. W., Lee, H., Eun, B. W., Choo, E. J., Lee, J., Kim, Y. K., et al. (2014) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2014.29.1.132 · Cited by 28
Management of Infectious Complications in the Hematopoietic Stem Cell Transplant Recipient
Nichols, W. G. (2003) · Journal of Intensive Care Medicine · doi:10.1177/0885066603258009 · Cited by 27
Clinical Pharmacology of Anti-Infective Drugs
Wade, K. C., & Benjamin, D. K. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6400-8.00037-7 · Cited by 26
Competition between RSV and influenza: Limits of modelling inference from surveillance data
Waterlow, N. R., Flasche, S., Minter, A., & Eggo, R. M. (2021) · Epidemics · doi:10.1016/j.epidem.2021.100460 · Cited by 26
Inhibition of Novel Reassortant Avian Influenza H7N9 Virus Infection in vitro with Three Antiviral Drugs, Oseltamivir, Peramivir and Favipiravir
Cao, R., Xiao, J.-H., Cao, B., Li, S., Kumaki, Y., & Zhong, W. (2013) · Antiviral chemistry & chemotherapy · doi:10.3851/imp2672 · Cited by 26
Population Pharmacokinetics of Oseltamivir: Pediatrics through Geriatrics
Kamal, M. A., Wart, S. A. V., Rayner, C. R., Subramoney, V., Reynolds, D. K., Bulik, C. C., Smith, P. F., Bhavnani, S. M., Ambrose, P. G., & Forrest, A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02438-12 · Cited by 26
Novel therapy for asthma
Hansel, T. T., LARCHÉ, M. J., Bryan, S. A., & Barnes, P. J. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.1.25 · Cited by 26
Update on Pharmacologic Therapy for Chronic Obstructive Pulmonary Disease
Ferguson, G. T. (2000) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(05)70180-5 · Cited by 26
A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and TastePreprint
Chupp, G. L., Spichler-Moffarah, A., Søgaard, O. S., Esserman, D., Dziura, J., Danzig, L. E., Chaurasia, R., Patra, K. P., Salovey, A., Núñez, Á., et al. (2022) · medRxiv · doi:10.1101/2022.01.28.22270035 · Cited by 28
Engineered Mycobacterium tuberculosis triple-kill-switch strain provides controlled tuberculosis infection in animal models
Wang, X., Su, H.-W., Wallach, J. B., Wagner, J. C., Braunecker, B. J., Gardner, M. J., Guinn, K. M., Howard, N. C., Klevorn, T., Lin, K., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-024-01913-5 · Cited by 25
Early therapy with the neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment
Gillissen, A., & Höffken, G. (2002) · Medical Microbiology and Immunology · doi:10.1007/s00430-002-0139-9 · Cited by 25
Influenza vaccination might reduce the risk of ischemic stroke in patients with atrial fibrillation: A population-based cohort study
Kao, P., Liu, J., Hsu, Y.-P., Sung, L., Yang, T.-Y., Hao, W., Lin, Y., & Wu, S. (2017) · Oncotarget · doi:10.18632/oncotarget.22352 · Cited by 25
Influenza
Cram, P. M., Blitz, S. G., Monto, A. S., & Fendrick, A. M. (2001) · PharmacoEconomics · doi:10.2165/00019053-200119030-00001 · Cited by 25
Potential of antiviral drug oseltamivir for the treatment of liver cancer
Huang, P., Chiu, C., Hsiao, M.-H., Yow, J., Tzang, B., & Hsu, T. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5289 · Cited by 24
Enhanced detection of respiratory viruses using cryopreserved R-Mix ReadyCells
Kim, J. S., Kim, S. H., Bae, S. Y., Lim, C. S., Kim, Y. K., Lee, K. N., & Lee, C. K. (2008) · Journal of Clinical Virology · doi:10.1016/j.jcv.2008.03.015 · Cited by 24
Oseltamivir (Tamiflu) Induced Depressive Episode in a Female Adolescent
Chung, S., & Joung, Y. (2010) · Psychiatry Investigation · doi:10.4306/pi.2010.7.4.302 · Cited by 24
Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza
Scott, C., Kankanala, J., Foster, T. L., Goldhill, D. H., Bao, P., Simmons, K. J., Pingen, M., Bentham, M., Atkins, E., Loundras, E.-A., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008716 · Cited by 23
Anti-inflammatory effects of medications used for viral infection-induced respiratory diseases
Yamaya, M., Kikuchi, A., Sugawara, M., & Nishimura, H. (2022) · Respiratory Investigation · doi:10.1016/j.resinv.2022.11.002 · Cited by 24
Community pharmacy rapid influenza A and B screening
Papastergiou, J., Folkins, C., Li, W., & Young, L. (2016) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/1715163516629157 · Cited by 23
IN THE ELDERLY
Wick, J. Y., & Zanni, G. R. (2004) · The Consultant Pharmacist · doi:10.4140/tcp.n.2004.195 · Cited by 23
Pandemic Influenza and Its Implications for Transplantation
Kumar, D., & Humar, A. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01364.x · Cited by 23
Prevention and Control of Influenza
Lee, P. P. (2003) · Southern Medical Journal · doi:10.1097/01.smj.0000084985.13843.89 · Cited by 23
Experience with Oseltamivir in the Control of Nursing Home Influenza A Outbreak.
Shijubo, N., Yamada, G., Takahashi, M., Tokunoh, T., Suzuki, T., & Abe, S. (2002) · Internal Medicine · doi:10.2169/internalmedicine.41.366 · Cited by 23
Economic Evaluation of Oseltamivir Phosphate for Postexposure Prophylaxis of Influenza in Long‐Term Care Facilities
Risebrough, N. A., Bowles, S. K., Simor, A. E., McGeer, A., & OH, P. I. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53162.x · Cited by 23
Human Challenge Studies: A Review of Adequacy of Reporting Methods and Results
Kalil, J. A., Halperin, S. A., & Langley, J. M. (2012) · Future Microbiology · doi:10.2217/fmb.12.15 · Cited by 21
Phenotypic Differences in Virulence and Immune Response in Closely Related Clinical Isolates of Influenza A 2009 H1N1 Pandemic Viruses in Mice
Camp, J. V., Chu, Y. K., Chung, D.-H., McAllister, R. C., Adcock, R. S., Gerlach, R. L., Wiemken, T. L., Peyrani, P., Ramírez, J. A., Summersgill, J. T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056602 · Cited by 21
Possible Neuropsychiatric Reaction to High‐Dose Oseltamivir during Acute 2009 H1N1 Influenza A Infection
Nakamura, K., Schwartz, B. S., Lindegårdh, N., Keh, C. E., & Guglielmo, B. J. (2010) · Clinical Infectious Diseases · doi:10.1086/651166 · Cited by 21
The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans
Oh, J., Lee, S., Lee, H., Cho, J., Yoon, S. H., Jang, I., Yu, K., & Lim, K. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176320 · Cited by 21
Efficacy of Oseltamivir Phosphate to Horses Inoculated with Equine Influenza A Virus
Yamanaka, T., Tsujimura, K., Kondo, T., Seiji, H. O. B. O., & Matsumura, T. (2006) · Journal of Veterinary Medical Science · doi:10.1292/jvms.68.923 · Cited by 21
Clinical and laboratory diagnosis of influenza virus infections.
Newton, D. W., Treanor, J. J., & Menegus, M. A. (2000) · PubMed · Cited by 21
Self-citation

Authors: Hayden, F. G., Treanor, J. J., Fritz, R. S., Lobo, M., Betts, R. F., Miller, M., Kinnersley, N., Mills, R. G., Ward, P., & Straus, S. E.
Affiliations: University of Virginia (US)
ORCID: Hayden, Frederick G.
Kinnersley, Nelson
Mills, Roger G.
Ward, Penelope
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 1999-10-06
Volume: 282
Issue: 13
Pages: 1240
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.282.13.1240
OpenAlex: W2072658090
Cited by: 550
References: 30
Citations by year: 2026: 10 · 2025: 11 · 2024: 8 · 2023: 10 · 2022: 17 · 2021: 14 · 2020: 17 · 2019: 8 · 2018: 12 · 2017: 16 · 2016: 22 · 2015: 13 · 2014: 23 · 2013: 22 · 2012: 22
FWCI: 30.45
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (n01co056000-057)
National Cancer Institute (N01 CO 56000)
Topics: Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Keywords: oseltamivir, neuraminidase inhibitors, influenza A virus, antiviral prophylaxis, antiviral therapy, viral shedding, H1N1 influenza, drug safety and tolerability, dose comparison, zanamivir, influenza C, influenza D virus, influenza E
MeSH terms: Administration, Oral, Adolescent, Adult, Amines, Dose-Response Relationship, Drug, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Influenza, Human, Male, Nausea, Neuraminidase, Nose, Influenza A virus, Area Under Curve, Oseltamivir

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza: Randomized Controlled Trials for Prevention and Treatment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks